Legal aspects of marketing authorization for medicinal products in the territory of Poland
Abstract
Marketing authorisation procedure aims at ensuring that patients have access to medicinal products which meet scientifically proven quality, therapeutic efficacy and safety of use standards. Marketing authorisation constitutes a sine qua non condition for placing a medicinal product on a market. Only in extraordinary situations is trading in medicinal products which have not been granted marketing authorization lawfully admissible. Producers of pharmaceuticals who have been granted marketing authorisation for a medicinal product, are obligated to develop a system supervising the safety of pharmacotherapy, the so called pharmacovigilance. The system collects and registers adverse reactions, which is of utmost importance as diligently performed assessment of the medicine safety profile allows providing full information on the medicine, which in turn facilitates the choice of appropriate medicinal product for a given patient. The above-mentioned process continues throughout the period of use of a medicinal product for, the moment new fact are reported, the efficacy assessment of the medicinal product in question is performed anew.
Keywords:
pharmaceutical law, medicinal products, procedures for marketing authorisation of medicinal productsReferences
Biadun D., Marketing Medicinal Products in the light of Judicial Practice, Warsaw 2012.
Kondrat M. (editor) Pharmaceutical Law. Commentary, Warsaw 2016.
Krekora M., Świerczyński M., Traple E., Pharmaceutical Law. Regulation and civil issues, Warsaw 2008.
Krekora M., Świerczyński M., Traple E, Pharmaceutical Law, Warsaw 2011.
Maciejczyk A., Introduction, [in:] Supervising Safety of Pharmacotherapy. Pharmacovigilance, editors. I .Łagocka, A. Maciejczyk, Warsaw 2008.
Olszewski W. L. (editor) Pharmaceutical Law. Commentary, Warsaw 2016.
Roszak M., Parallel Trade in Medicinal Products in European Union Law. The Limits of the Free Movement of Goods on Pharmaceutical Market, Warsaw 2014.
Shih H.H, P. Miller, D.C. Harnish, An Overview of Discovery and Development Process for Biologics [in:] W. Wang, M. Singh (editor), Biological Drug Products: Development and Strategies, Wiley 2013.
Siwiec M., Differences Between Medicinal Products, Food Supplements, Medical Devices and Foodstuffs for Particular Purposes. Practical Commentary, LEX on-line.
Sławatyniec Ł. (editor), Pharmaceutical Law Medicines Reimbursement, Warsaw 2013.
Świerczyński M. (editor), Biological Medicinal Products. Legal Aspects, Warsaw 2016.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International License.
